Passos Livia S A, Nunes Maria Carmo P, Zilla Peter, Yacoub Magdi H, Aikawa Elena
The Center for Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hospital das Clínicas e Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Glob Cardiol Sci Pract. 2020 Nov 30;2020(2):e202026. doi: 10.21542/gcsp.2020.26.
Rheumatic heart disease (RHD) is a major burden in low- to mid-income countries, where each year it accounts for over a million premature deaths associated with severe valve disease. Life-saving valve replacement procedures are not available to the majority of affected RHD patients, contributing to an increased risk of death in young adults and creating a devastating impact. In December 2017, a group of representatives of major cardiothoracic societies and industry, discussed the plight of the millions of patients who suffer from RHD. A comprehensive solution based on this global partnership was outlined in "The Cape Town Declaration on Access to Cardiac Surgery in the Developing World". The key challenge in controlling RHD is related to identification and removal of barriers to the translation of existing knowledge into policy, programs, and practice to provide high-quality care for patients with RHD. This review provides an overview on RHD by emphasizing the disease medical and economic burdens worldwide, risk factors, recent advance for early disease detection, and overall preventive strategies.
风湿性心脏病(RHD)是低收入和中等收入国家的一项重大负担,每年它导致超过100万例与严重瓣膜疾病相关的过早死亡。大多数受影响的风湿性心脏病患者无法获得挽救生命的瓣膜置换手术,这增加了年轻人的死亡风险,并造成了毁灭性影响。2017年12月,一群心胸外科主要学会和行业的代表讨论了数百万风湿性心脏病患者的困境。《发展中世界心脏手术可及性开普敦宣言》概述了基于这种全球伙伴关系的全面解决方案。控制风湿性心脏病的关键挑战与识别和消除将现有知识转化为政策、项目和实践以向风湿性心脏病患者提供高质量护理的障碍有关。本综述通过强调全球范围内该疾病的医学和经济负担、危险因素、早期疾病检测的最新进展以及总体预防策略,对风湿性心脏病进行了概述。